Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.
June 26, 2026
1 min read
Save
FDA approves Skyrizi for pediatric use in psoriatic disease
The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active psoriatic arthritis, AbbVie announced in a press release.
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
FDA Expands Risankizumab Label in Psoriatic Disease
What's Going On With AbbVie Stock Monday? - AbbVie (NYSE:ABBV)
Pediatric Dermatology Use by Race/Ethnicity
Incyte drops lawsuit as CMS relents on classification of Opzelura
The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates…
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to…
IL-23 inhibitor lands indications for kids 6 years and up
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest…
The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced in a…
